Scott brings over twenty years of strategic and operational experience within the pharmaceutical industry. Scott most recently served as AbbVie’s VP Scientific Affairs and Head of AbbVie Ventures. Under his leadership, the ventures group expanded its investment portfolio to include over 20 active companies. In addition, Scott served as one of AbbVie’s primary spokespersons for R&D to global media, governmental officials and investors. Previously, as VP and Head of Pharmaceutical Development, he led the global organization responsible for the development of AbbVie’s portfolio of early and late-stage clinical preregistration pipeline compounds as well as marketed compounds within therapeutic areas including oncology, neurology, immunology, renal, infectious disease and women’s/men’s health. Prior to AbbVie’s launch, Scott held positions of increasing responsibility in drug development within R&D at Abbott Laboratories. Currently Scott sits on the boards of Axial Therapeutics and Horizon and serves as a Venture Partner at Abingworth. Scott earned his MD at the Johns Hopkins University School of Medicine and completed his residency in Ophthalmology at Harvard Medical School.